Novacyt (FR:ALNOV) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Novacyt S.A. reports a robust first half of 2024, with revenues of £10.3m and a significant increase in gross profit to £26.5m, thanks to a successful dispute settlement with the DHSC and strategic growth in their Reproductive Health and NIPT businesses. The company has also made substantial cost savings post-acquisition of Yourgene, maintaining a strong cash position at £32.9m while being debt-free, setting a strong foundation for future expansion and product development.
For further insights into FR:ALNOV stock, check out TipRanks’ Stock Analysis page.
